DCA Clinical Trials Successful: Drug Could Be the New Panacea

Reports claim that Canadian doctors have successfully finished the inexpensive drug, DCA trails in cancer patients.

The drug is known for its tumor-shrinking abilities that could be the long sought panacea for cancer.

The results of the study were published in Science Translational Medicine, a journal of the American Association of the Advancement of Science on Wednesday.

The study that was led by Dr. Evangelos Michelakis, from the University of Alberta was performed on a small sample of five people who were suffering from brain tumor and had a life expectancy of only seven months. Further, at the end of the study four of the five patients were still alive and several were free from cancer.

Dr. Michelakis stated that the results of the study prove that drug can have an effect on human tumors and not just animal tumors.

He also stated that since the sample size of the study was too small, hence it does not to permit any definitive conclusion.

Experts say that DCA, or dichloroacetate reverses the glucose addiction that cancer cells have, thereby inhibiting cancer growth.

Though medical experts feel that the dug could be answer for cancer treatment, but in 2007 following the lab results of Michelakis on animals, patients were told that the drug could not be patented.

Since the drug could not be patented; drug companies refused to provide funding for the extensive clinical trials that were needed to make it a viable treatment option.

Reports claim that it was the efforts of the public for the purpose that fundraised $800,000. Following the public efforts Hecht Foundation and the federal government also contributed $1.5-million for the trials.